Garret M. Hampton

11.8k citations

93 papers · 9.1k indexed · 4 hit papers · h-index 45

Molecular Biology top 1%
Oncology top 1%
Cancer Research top 0.5%
Pulmonary and Respiratory Medicine top 2%
Genetics top 2%

Co-authors: Henry F. Frierson Lisa M. Sapinoso S Kern Christopher A. Moskaluk Peter G. Schultz Andrew I. Su Dan Theodorescu Steven M. Powell
Topics: Cancer Genomics and Diagnostics (18 papers)Gene expression and cancer classification (13 papers)RNA modifications and cancer (13 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Proceedings of the National Academy of Sciences Nature Communications Nature Genetics
Partner nations: United States United Kingdom China

In The Last Decade

Garret M. Hampton

93 papers receiving 8.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Large-scale analysis of the human and mouse transcriptomes

2002 1.2k citations Keith A. Ching, Lisa M. Sapinoso et al. profile →
c-Myc Can Induce DNA Damage, Increase Reactive Oxygen Species, and Mitigate p53 Function

2002 720 citations Garret M. Hampton et al. profile →
Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer

2001 546 citations John Welsh, Patrick P. Zarrinkar et al. profile →
Molecular classification of human carcinomas by use of gene expression signatures.

2001 506 citations John Welsh, Lisa M. Sapinoso et al. profile →

Peers

Countries citing papers authored by Garret M. Hampton

Since Specialization

Citations

This map shows the geographic impact of Garret M. Hampton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Garret M. Hampton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Garret M. Hampton more than expected).

Fields of papers citing papers by Garret M. Hampton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Garret M. Hampton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Garret M. Hampton. The network helps show where Garret M. Hampton may publish in the future.

Co-authorship network of co-authors of Garret M. Hampton

This figure shows the co-authorship network connecting the top 25 collaborators of Garret M. Hampton. A scholar is included among the top collaborators of Garret M. Hampton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Garret M. Hampton. Garret M. Hampton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β 2016 ·Cancer Research ·Yoshito Nakanishi,Kimberly Walter,Jill M. Spoerke,Carol O’Brien,Ling Huw,Garret M. Hampton,Mark R. Lackner	55
2	Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC 2016 ·Annals of Oncology ·Marcin Kowanetz,Wei Zou,David S. Shames,(unknown),Naiyer A. Rizvi,Alexander I. Spira,Garrett M. Frampton,Vincent Lévêque,Shannon L. Flynn,Simonetta Mocci,G. Shankar,Roel Funke,M. Ballinger,Daniel Waterkamp,A. Sandler,Garret M. Hampton,Lukas C. Amler,Priti S. Hegde,Matthew D. Hellmann	34
3	High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing 2014 ·Clinical Cancer Research ·Richard Bourgon,Shan Lu,Yibing Yan,Mark R. Lackner,Weiru Wang,Victor Weigman,David Wang,Yinghui Guan,Lisa Ryner,Hartmut Koeppen,Rajesh Patel,Garret M. Hampton,Lukas C. Amler,Yulei Wang	52
4	Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples 2014 ·Breast Cancer Research and Treatment ·Timothy R. Wilson,Yuanyuan Xiao,Jill M. Spoerke,Jane Fridlyand,Hartmut Koeppen,(unknown),Ling Huw,(unknown),(unknown),Erica Schleifman,Rupal Desai,Ling Fu,Teiko Sumiyoshi,Joyce O’Shaughnessy,Garret M. Hampton,Mark R. Lackner	21
5	HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors 2013 ·Molecular Cancer Therapeutics ·Elicia Penuel,Congfen Li,(unknown),Luciana Burton,Kyra J. Cowan,Mark Merchant,Robert L. Yauch,Premal H. Patel,Amy Peterson,Garret M. Hampton,Mark R. Lackner,Priti S. Hegde	20
6	Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib 2012 ·Clinical Cancer Research ·Elizabeth A. Punnoose,Siminder Atwal,Weiqun Liu,Rajiv Raja,Bernard M. Fine,Brett Hughes,Rodney J. Hicks,Garret M. Hampton,Lukas C. Amler,Andrea Pirzkall,Mark R. Lackner	341
7	DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer 2012 ·Clinical Cancer Research ·Walter Kim,Thomas Holcomb,Tom Januario,Pan Du,Marie Evangelista,(unknown),Leonardo Iniguez,Robert Soriano,Ling Huw,Howard M. Stern,Zora Modrušan,Somasekar Seshagiri,Garret M. Hampton,Lukas C. Amler,Richard Bourgon,Robert L. Yauch,David S. Shames	66
8	Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models 2012 ·Clinical Cancer Research ·Jill M. Spoerke,Carol O’Brien,Ling Huw,Hartmut Koeppen,Jane Fridlyand,Rainer K. Brachmann,Peter M. Haverty,Ajay Pandita,Sankar Mohan,Deepak Sampath,Lori S. Friedman,Leanne Ross,Garret M. Hampton,Lukas C. Amler,David S. Shames,Mark R. Lackner	149
9	ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors 2012 ·Molecular Cancer Therapeutics ·Georgia Hatzivassiliou,Bonnie Liu,Carol O’Brien,Jill M. Spoerke,Klaus P. Hoeflich,Peter M. Haverty,Robert Soriano,William F. Forrest,Sherry Heldens,Huifen Chen,Karen Toy,Connie Ha,Wei Zhou,Kyung Song,Lori S. Friedman,Lukas C. Amler,Garret M. Hampton,John G. Moffat,Marcia Belvin,Mark R. Lackner	155
10	Prostate cancer – a biomarker perspective 2012 ·Frontiers in Endocrinology ·Yanqiu Liu,Priti S. Hegde,Feng‐Min Zhang,Garret M. Hampton,Shidong Jia	20
11	Profiling Bladder Cancer Organ Site-Specific Metastasis Identifies LAMC2 as a Novel Biomarker of Hematogenous Dissemination 2009 ·American Journal Of Pathology ·Steven C. Smith,(unknown),Matthew D. Nitz,Henry F. Frierson,Mark E. Smolkin,Garret M. Hampton,Wael El‐Rifai,Dan Theodorescu	29
12	An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma 2007 ·Clinical Cancer Research ·Ivo Meinhold‐Heerlein,Dirk Bauerschlag,Yingyao Zhou,Lisa M. Sapinoso,Keith A. Ching,Henry F. Frierson,Karen Bräutigam,Jalid Sehouli,Elmar Stickeler,Dominique Könsgen,Felix Hilpert,Constantin S. von Kaisenberg,Jacobus Pfisterer,Thomas Bauknecht,W. Jonat,Norbert Arnold,Garret M. Hampton	41
13	Overexpression of CEBPβ correlates with decreased TFF1 in gastric cancer 2005 ·Oncogene ·Narendra V. Sankpal,Christopher A. Moskaluk,Garret M. Hampton,Steven M. Powell	23
14	RNAi and HTS: exploring cancer by systematic loss-of-function 2004 ·Oncogene ·Aarron Willingham,Quinn L. Deveraux,Garret M. Hampton,Pedro Aza‐Blanc	48
15	Overexpression of the 32‐kilodalton dopamine and cyclic adenosine 3′,5′‐monophosphate‐regulated phosphoprotein in common adenocarcinomas 2003 ·Cancer ·(unknown),Christopher A. Moskaluk,Alexander Zaika,Garret M. Hampton,Steven M. Powell,Henry F. Frierson,(unknown)	52
16	Activation and Suppression of the TRAIL Death-Receptor Pathway in Chemotherapy Sensitive and Resistant Follicular Lymphoma Cells 2003 ·Cancer Biology & Therapy ·Klaus W. Wagner,(unknown),(unknown),Deborah Knee,Garret M. Hampton,Marc Nasoff,Quinn L. Deveraux	8
17	An integrated view of aromatase and its inhibition 2003 ·The Journal of Steroid Biochemistry and Molecular Biology ·William R. Miller,Thomas Anderson,Dean B. Evans,Andreas Krause,Garret M. Hampton,J. Michael Dixon	34
18	Microsatellite instability in cervical carcinoma 2001 ·European Journal of Obstetrics & Gynecology and Reproductive Biology ·Tony K.H. Chung,(unknown),Garret M. Hampton,Vivian W. Wang,Tak Hong Cheung,Y.F. Wong	4
19	Arrays of Arrays for High-Throughput Gene Expression Profiling 2001 ·Genome Research ·Patrick P. Zarrinkar,James Mainquist,Matthew T. Zamora,David L. Stern,John Welsh,Lisa M. Sapinoso,Garret M. Hampton,David J. Lockhart	30
20	Identification and Characterization of Novel Genes Located at the t(1;15)(p36.2;q24) Translocation Breakpoint in the Neuroblastoma Cell Line NGP 2000 ·Genomics ·Lukas C. Amler,Anja Bauer,Raffaella Corvi,Susanne Dihlmann,Christian Praml,Webster K. Cavenee,Manfred Schwab,Garret M. Hampton	18

About Garret M. Hampton

Garret M. Hampton is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 93 papers that have together received 9.1k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (18 papers), Gene expression and cancer classification (13 papers) and RNA modifications and cancer (13 papers). The work is most often cited by research in Cancer Research (1.9k citations), Oncology (2.6k citations) and Molecular Biology (5.6k citations). Garret M. Hampton has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Henry F. Frierson, Lisa M. Sapinoso, S Kern, Christopher A. Moskaluk, Peter G. Schultz, Andrew I. Su, Dan Theodorescu, Steven M. Powell, Mary T. Galgano and John Welsh. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Communications and Nature Genetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact